Interleukin 35: Critical regulator of immunity and lymphocyte-mediated diseases

Cytokine and Growth Factor Reviews

Volumn 26, Issue 5, 2015, Pages 587-593

  Egwuagu, Charles E ^a   Yu, Cheng Rong ^a   Sun, Lin ^a   Wang, Renxi ^b  

^a NATIONAL EYE INSTITUTE   (United States)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Adoptive B cell therapy; Autoimmune diseases; Breg; Cytokine therapy; I35 Breg; IL 12 family cytokines; Interleukin 35; ITR35; Regulatory B cells

Indexed keywords

EPSTEIN BARR VIRUS INDUCED GENE 3; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 27; INTERLEUKIN 27P28; INTERLEUKIN 35; INTERLEUKIN 6; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE TYK2; STAT1 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS GLYCOPROTEIN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE UVEITIS; B LYMPHOCYTE; BINDING AFFINITY; CARCINOGENESIS; CELL EXPANSION; CULTURE MEDIUM; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG ACTIVITY; EPSTEIN BARR VIRUS; EXPERIMENTAL AUTOIMMUNE UVEITIS; GAMMA DELTA T LYMPHOCYTE; HEMATOPOIETIC CELL; HUMAN; IMMUNE SUPPRESSIVE ACTIVITY; IMMUNOPRECIPITATION; IN VITRO STUDY; INNATE IMMUNITY; LANGERHANS CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MACROPHAGE; MONOCYTE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; T LYMPHOCYTE; TH17 CELL; X RAY CRYSTALLOGRAPHY; ANIMAL; IMMUNOLOGY; NEUROLOGIC DISEASE; PATHOLOGY; REGULATORY T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; B-LYMPHOCYTES, REGULATORY; HUMANS; INTERLEUKINS; T-LYMPHOCYTES, REGULATORY;

EID: 84941942616     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.07.013     Document Type: Short Survey

References (51)

1. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995, 268:251-255.
2. Dinarello C.A. Historical insights into cytokines. Eur. J. Immunol. 2007, 37(Suppl. 1):S34-S45.
3. Wang R.X., Yu C.R., Dambuza I.M., Mahdi R.M., Dolinska M.B., Sergeev Y.V., et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 2014, 20:633-641.
4. Shen P., Roch T., Lampropoulou V., O'Connor R.A., Stervbo U., Hilgenberg E., et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507:366-370.
5. Sawant D.V., Hamilton K., Vignali D.A. Interleukin-35: expanding its job profile. J. Interferon Cytokine Res. 2015, 10.1089/jir.2015.0015.
6. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
7. Sun L., He C., Nair L., Yeung J., Egwuagu C.E. Interleukin 12 (IL-12) family cytokines: role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokine 2015, S1043-4666(15)00049-6.
8. Egwuagu C.E., Yu C.R. Interleukin 35-producing B cells (i35-Breg): a new mediator of regulatory B-cell functions in CNS autoimmune diseases. Crit. Rev. Immunol. 2015, 35:49-57.
9. Vignali D.A., Kuchroo V.K. IL-12 family cytokines: immunological playmakers. Nat. Immunol. 2012, 13:722-728.
10. Darnell J.E. STATs and gene regulation. Science 1997, 277:1630-1635.
11. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
12. Kobayashi M., Fitz L., Ryan M., Hewick R.M., Clark S.C., Chan S., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 1989, 170:827-845.
13. Liu J., Cao S., Herman L.M., Ma X. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J. Exp. Med. 2003, 198:1265-1276.
14. Masumi A., Tamaoki S., Wang I.M., Ozato K., Komuro K. IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages. FEBS Lett. 2002, 531:348-353.
15. Kano S., Sato K., Morishita Y., Vollstedt S., Kim S., Bishop K., et al. The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T cells. Nat. Immunol. 2008, 9:34-41.
16. Unutmaz D., Vilcek J. IRF1: a deus ex machina in TH1 differentiation. Nat. Immunol. 2008, 9:9-10.
17. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
18. Watford W.T., Moriguchi M., Morinobu A., O'Shea J.J. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003, 14:361-368.
19. Gaffen S.L., Jain R., Garg A.V., Cua D.J. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 2014, 14:585-600.
20. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
21. Kastelein R.A., Hunter C.A., Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 2007, 25:221-242.
22. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
23. Villarino A.V., Hunter C.A. Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res. Ther. 2004, 6:225-233.
24. Hunter C.A., Kastelein R. Interleukin-27: balancing protective and pathological immunity. Immunity 2012, 37:960-969.
25. Pflanz S., Hibbert L., Mattson J., Rosales R., Vaisberg E., Bazan J.F., et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 2004, 172:2225-2231.
26. Owaki T., Asakawa M., Fukai F., Mizuguchi J., Yoshimoto T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol. 2006, 177:7579-7587.
27. Hall A.O., Silver J.S., Hunter C.A. The immunobiology of IL-27. Adv. Immunol. 2012, 115:1-44.
28. Fitzgerald D.C., Zhang G.X., El-Behi M., Fonseca-Kelly Z., Li H., Yu S., et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 2007, 8:1372-1379.
29. Awasthi A., Carrier Y., Peron J.P., Bettelli E., Kamanaka M., Flavell R.A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 2007, 8:1380-1389.
30. Batten M., Li J., Yi S., Kljavin N.M., Danilenko D.M., Lucas S., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 2006, 7:929-936.
31. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., et al. T(H)17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 2007, 13:711-718.
32. Lee Y.S., Amadi-Obi A., Yu C.R., Egwuagu C.E. Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology 2011, 132:492-502.
33. Devergne O., Hummel M., Koeppen H., Le Beau M.M., Nathanson E.C., Kieff E., et al. A novel Interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J. Virol. 1996, 70:1143-1153.
34. Devergne O., Birkenbach M., Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:12041-12046.
35. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
36. Niedbala W., Wei X.Q., Cai B., Hueber A.J., Leung B.P., McInnes I.B., et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol. 2007, 37:3021-3029.
37. Aparicio-Siegmund S., Moll J.M., Lokau J., Grusdat M., Schroder J., Plohn S., et al. Recombinant p35 from bacteria can form Interleukin (IL-)12, but Not IL-35. PLOS ONE 2014, 9:e107990.
38. Gavin M.A., Rasmussen J.P., Fontenot J.D., Vasta V., Manganiello V.C., Beavo J.A., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007, 445:771-775.
39. Rudensky A.Y., Gavin M., Zheng Y. FOXP3 and NFAT: partners in tolerance. Cell 2006, 126:253-256.
40. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 2010, 11:1093-1101.
41. Yoshizaki A., Miyagaki T., DiLillo D.J., Matsushita T., Horikawa M., Kountikov E.I., et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012, 491:264-268.
42. Boulanger M.J., Chow D.C., Brevnova E.E., Garcia K.C. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003, 300:2101-2104.
43. Garbers C., Hermanns H.M., Schaper F., Muller-Newen G., Grotzinger J., Rose-John S., et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012, 23:85-97.
44. Collison L.W., Delgoffe G.M., Guy C.S., Vignali K.M., Chaturvedi V., Fairweather D., et al. The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 2012, 13:290-299.
45. Adam N., Rabe B., Suthaus J., Grotzinger J., Rose-John S., Scheller J. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J. Virol. 2009, 83:5117-5126.
46. Suthaus J., Adam N., Grotzinger J., Scheller J., Rose-John S. Viral Interleukin-6: structure, pathophysiology and strategies of neutralization. Eur. J. Cell Biol. 2011, 90:495-504.
47. Chalaris A., Garbers C., Rabe B., Rose-John S., Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur. J. Cell Biol. 2011, 90:484-494.
48. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 2011, 1813:878-888.
49. Nussenblatt R.B. The natural history of uveitis. Int. Ophthalmol. 1990, 14:303-308.
50. Nussenblatt R.B. Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest Ophthalmol. Vis. Sci. 1991, 32:3131-3141.
51. Caspi R.R., Roberge F.G., Chan C.C., Wiggert B., Chader G.J., Rozenszajn L.A., et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 1988, 140:1490-1495.